Study shows biocept's switch-blocker technology enhances performance of conventional pcr-based liquid biopsy assays in detecting rare cancer mutations

San diego--(business wire)--published abstract shows biocept's switch-blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.

BIOC Ratings Summary

BIOC Quant Ranking